Form 4: ALX Oncology Executive Sells Shares for Tax

ALX Oncology's SVP of Finance and CAO, Shelly Pinto, sold 611 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Shelly Pinto, SVP, Finance and CAO of ALX Oncology Holdings Inc. (ALXO), sold 611 shares of common stock.
• The sale occurred on August 15, 2025, at a weighted average price of $0.6404 per share, with prices ranging from $0.64 to $0.66.
• The purpose of the sale was to satisfy tax obligations arising from the vesting of restricted stock units.
• Following this transaction, Shelly Pinto beneficially owns 89,198 shares of ALX Oncology common stock.
• This total includes 3,000 shares acquired through the company's employee stock purchase plan on June 30, 2025.
• The transaction was executed under a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing reports a routine insider sale of shares to cover tax obligations from restricted stock unit vesting, which is a common and expected event. The simultaneous acquisition of shares through an employee stock purchase plan indicates continued insider investment, balancing the impact of the tax-related sale.

Positives

• The reporting person acquired 3,000 shares through the company's employee stock purchase plan on June 30, 2025, indicating continued participation in company equity programs.
• The sale of shares was non-discretionary, specifically to cover tax obligations related to restricted stock unit vesting, rather than a voluntary divestment.

Negatives

• The sale of 611 shares by a senior executive reduces their direct beneficial ownership in the company.

Future Outlook

NA

Management Comments

• The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

Industry Context

NA

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, offset by the non-discretionary nature of the sale and continued participation in equity programs.

Key Dates

Recommendation

The filing details a routine insider transaction where an executive sold a small number of shares to cover tax obligations from restricted stock unit vesting. This is a common occurrence and not indicative of a change in company fundamentals or management's long-term view. The executive also acquired shares through an employee stock purchase plan, suggesting continued confidence. Therefore, the filing itself does not provide new information that would warrant a change in investment recommendation.

Keywords

ALX Oncology, ALXO, insider trading, Form 4, stock sale, executive compensation, Shelly Pinto, restricted stock units, tax obligations